Tri-modality Therapy in Esophageal Carcinoma is at a Crossroad
- PMID: 39548052
- DOI: 10.1245/s10434-024-16499-9
Tri-modality Therapy in Esophageal Carcinoma is at a Crossroad
References
-
- Nakamura K, Kato K, Igaki H, et al. Three-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT study). Jpn J Clin Oncol. 2013;43:752–5. - DOI - PubMed
-
- Wu YY, Dai L, Yang YB, et al. Long-term survival and recurrence patterns in locally advanced esophageal squamous cell carcinoma patients with pathologic complete response after neoadjuvant chemotherapy followed by surgery. Ann Surg Oncol. 2024. https://doi.org/10.1245/s10434-023-14809-1 . - DOI - PubMed - PMC
-
- van der Wilk BJ EB, Wijnhoven BPL, Lagarde SM, Rosman C, Noordman BJ, et al. Neoadjuvant chemoradiotherapy followed by surgery versus active surveillance for oesophageal cancer (SANO-trial): a phase-III stepped-wedge cluster randomised trial. Ann Oncol. 2023;1:1317. - DOI
Publication types
LinkOut - more resources
Full Text Sources
